

REMARKS

Enclosed herewith in full compliance to 37 C.F.R. §§1.821-1.825 is a second Substitute Sequence Listing to be inserted into the specification as indicated above. The second Substitute Sequence Listing in no way introduces new matter into the specification. Also submitted herewith in full compliance to 37 C.F.R. §§1.821-1.825 is a disk copy of the second Substitute Sequence Listing. The disk copy of the second Substitute Sequence Listing, file "2185-0156P substitute.txt", is identical to the paper copy, except that it lacks formatting.

The second Substitute Sequence Listing is being submitted in order to correct a typographical error in the first Substitute Sequence Listing submitted on October 25, 2000 regarding SEQ ID NO: 9. The first substitute Sequence Listing erroneously characterized SEQ ID NO: 9 as an amino acid sequence; however, the Specification and original Sequence Listing as filed on June 25, 1999 identify SEQ ID NO: 9 as a nucleotide sequence. The second Substitute Sequence Listing submitted herewith correctly characterizes SEQ ID NO: 9 as a nucleotide sequence. This amendment in no way introduces new matter into the specification.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. \$1.16 or under 37 C.F.R. \$1.17; particularly, extension of time fees.

Respectfully submitted,
BIRCH, STEWART, KOLASCH & BIRCH, LLP

By

 #42,874



Gerald M. Murphy, Jr.

Reg. No. 28,977

P.O. Box 747

Falls Church, VA 22040-0747

(703) 205-8000

Attachments: Disk Copy of Sequence Listing
 Paper Copy of Sequence Listing
 Copy of Notice to Comply

GMM/CAM/CAV
2185-156P